131I-labeled metuximab combined with chemoembolization for unresectable hepatocellular carcinoma

doi:10.3748/wjg.v19.i47.9104

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 19, Issue 47

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6705)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

425

HTML

3678

Figures (1-1)

206

Tables (1-4)

205

Sum=4514

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1046

Download

1145

Sum=2191

Dec 21, 2013 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (24)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Dec 21, 2013; 19(47): 9104-9110
Published online Dec 21, 2013. doi: 10.3748/wjg.v19.i47.9104

Full Size Figure Download Figure

Figure 1 Kaplan-Meier curves of survival of patients in the test group receiving combination therapy (Licartin) and those in the control group receiving transcatheter arterial chemoembolization only (P < 0. 001). TACE: Transcatheter arterial chemoembolization.

Citation: He Q, Lu WS, Liu Y, Guan YS, Kuang AR. ¹³¹I-labeled metuximab combined with chemoembolization for unresectable hepatocellular carcinoma. World J Gastroenterol 2013; 19(47): 9104-9110
URL: https://www.wjgnet.com/1007-9327/full/v19/i47/9104.htm
DOI: https://dx.doi.org/10.3748/wjg.v19.i47.9104